International Journal of Economic Practices and Theories (IJEPT)
ISSN: 2247-7225
Volume 2026, Issue 1

Intellectual Property and Regulatory Strategy in Health-Tech Startups: A Review of Innovation, Market Entry, and Commercialization

Shivam Agarwal[1*], Sushil Pal[2], Sharad Kumar[3], Archana Rani[4],

[1]College of Allied and Healthcare Sciences, Teerthanker Mahaveer University, Moradabad, Uttar Pradesh, India.

[2]Charak Institute of Allied and Healthcare Studies Lucknow, Uttar Pradesh, India.

[3]School of Health and Paramedical Sciences, Vivek University, Bijnor, Uttar Pradesh, India.

[4]School of Health and Paramedical Sciences, Vivek University, Bijnor, Uttar Pradesh, India.

***Corresponding author:** Shivam Agarwal

Abstract:

Health-tech startups operate at the intersection of clinical need, engineering, software, data governance, intellectual property (IP), and regulated market access. A technically promising product may lose commercial value when ownership is unclear, patent filing is mistimed, freedom to operate is not examined, or regulatory evidence requirements are addressed only after design decisions have been fixed. This narrative review examines how IP strategy and regulatory planning can be integrated across the development and commercialization pathway for medical devices, diagnostics, digital health products, and artificial intelligence-enabled software. Publicly accessible literature and primary regulatory materials from international and national authorities were reviewed, with emphasis on India, the United States, and the European Union. The synthesis indicates that patents, trade secrets, copyright, trademarks, data rights, and contractual controls serve different functions and should be selected according to the technology, disclosure risk, product lifecycle, and business model. Regulatory classification, intended use, clinical evidence, quality management, cybersecurity, privacy, and post-market obligations should be considered before product architecture and claims are finalized. For startups, these domains are interdependent: patent scope can be affected by design changes; regulatory claims influence evidence burden and market positioning; data-access arrangements affect algorithm development; and licensing or investment diligence depends on demonstrable ownership and compliance readiness. An integrated strategy does not remove scientific, financial, or regulatory uncertainty, but it can reduce avoidable rework and improve the coherence of market-entry decisions. The review proposes a practical staged framework for aligning protectability, regulatory evidence, contracting, reimbursement, and post-market iteration while preserving patient safety and responsible innovation.

Keywords: commercialization; digital health; entrepreneurship; intellectual property; medical devices; regulatory science

Introduction

Health technologies increasingly combine hardware, software, algorithms, diagnostics, connectivity, and clinical workflows[1]. Their path from prototype to routine use is therefore shaped not only by technical performance but also by evidence generation, regulatory classification, ownership of inventions and data, reimbursement, procurement, and the ability to manufacture or deploy consistently[2]. Translation studies have repeatedly identified regulatory uncertainty, market fit[3], financing, and implementation readiness as common points of failure for early-stage medical technologies[4].

IP and regulation are often treated as sequential workstreams: first invent, then patent, then seek approval. In practice, the sequence is less linear. Public disclosure can affect patentability[5]; design changes made to meet safety or usability requirements can alter the protectable invention[6]; a broad clinical claim may increase the evidence burden; and an attractive patent portfolio does not itself establish freedom to operate or regulatory acceptability[7]. Patents also differ from trade secrets, copyright and trademarks in the type of asset protected and, in the disclosures, required[8].

For health-tech startups, the practical question is therefore not whether IP or regulatory strategy is more important[9], but how both can be coordinated with clinical validation and commercialization[10]. This review examines that interface, with particular attention to medical devices, software as a medical device (SaMD), digital health and AI-enabled products, and proposes a staged framework for early decisions that can be adapted across jurisdictions[11].

Methods

A focused narrative review was undertaken to synthesize legal, regulatory and translational considerations relevant to health-tech startups. Searches were conducted up to 2026 using PubMed/PMC and targeted web searches of open-access biomedical literature. Primary documents were retrieved from the World Health Organization (WHO), World Intellectual Property Organization (WIPO), International Medical Device Regulators Forum (IMDRF), US Food and Drug Administration (FDA), European Commission/EUR-Lex, Central Drugs Standard Control Organisation (CDSCO), and the Ministry of Electronics and Information Technology, Government of India. Search concepts included health technology startup, medical device commercialization, intellectual property, patents, trade secrets, technology transfer, SaMD, digital health regulation, AI medical device, market access, cybersecurity, clinical evaluation, and India medical device regulation.

Sources were included when they were publicly accessible and materially addressed at least one of four domains: IP protection or ownership; regulatory classification and evidence; product development and quality systems; or market entry and commercialization. Priority was given to primary regulatory documents, international guidance and peer-reviewed open-access reviews. Paywalled articles were not used as core references. Because the objective was integrative and practice-oriented rather than to estimate an effect size, formal risk-of-bias assessment and meta-analysis were not applicable. Regulatory statements were cross-checked against the issuing authority's current public guidance where available.

Intellectual property as a portfolio rather than a single patent

A patent provides a time-limited territorial right over an invention in exchange for public disclosure, whereas trade secret protection depends on maintaining commercially valuable information in confidence[5]. Copyright can protect software code, documentation and certain original expressions, while trademarks protect source-identifying signs and can become important as a product gains market recognition. These rights are complementary rather than interchangeable[6,7].

For a startup, an IP map should identify the technical invention, software components, datasets, know-how, design files, brand assets, and third-party inputs[8]. It should also distinguish ownership from permission to use. Founders may own pre-incorporation work unless it has been assigned; employees, consultants, universities, hospitals and contract developers may have different default rights under applicable contracts or law. Clean assignment records and clearly defined background and foreground IP are therefore important during licensing, investment and acquisition diligence[9].

Patent filing should be linked to the expected commercial product, not merely to the earliest prototype. Filing too late can expose the invention to disclosure risk, but filing very early may produce claims that do not cover later iterations or may consume limited resources before the product concept is stable. A staged approach can combine confidentiality[4,5], invention disclosure, prior-art review and appropriately timed filings. Freedom-to-operate analysis is a separate exercise: owning a patent does not necessarily mean that practicing the product will avoid infringement of third-party rights[9].

Table I. Strategic role of major IP mechanisms in health-tech development

IP mechanism	Typical health-tech asset	Strategic value	Main limitation/risk
Patent	Device architecture, sensor, assay, technical software implementation	Can support exclusivity, licensing and investment diligence	Territorial; time-limited; requires disclosure; scope may not cover later redesign
Trade secret	Algorithms, manufacturing know-how, calibration, processes, commercial methods	Useful for information that can remain confidential	Protection weakens if secrecy controls are inadequate or independent discovery occurs
Copyright	Source code, interface elements, manuals, documentation	Arises in original expression and supports software ownership	Does not protect the underlying idea or clinical function by itself
Trademark	Product, platform and company brand	Supports market identity and commercial goodwill	Does not protect technical functionality
Contracts/data rights	Licences, assignments, dataset access, development agreements	Clarifies ownership, permitted uses and commercialization rights	Poor drafting can create fragmented ownership or restrictions on scaling

Regulatory strategy should begin with intended use and classification

Regulatory obligations depend substantially on what the product is intended to do, who will use it, the clinical context and the consequences of an incorrect output[12]. The IMDRF SaMD framework and major national regulators use risk-based concepts to connect intended medical purpose with the level of evidence and oversight[13]. FDA similarly advises digital-health developers to determine whether a software function falls within device oversight, while the EU Medical Device Regulation (MDR) applies risk-based requirements to devices placed on the Union market[14].

In India, medical devices are regulated under the Medical Devices Rules, 2017, and CDSCO issued specific guidance on Medical Device Software in July 2026[15]. For software developers, this is particularly relevant because seemingly small changes in intended purpose, decision support, diagnosis, monitoring or therapeutic claims may change regulatory classification and documentation expectations[16].

A practical startup strategy is to write a concise intended-use statement before finalizing architecture or marketing claims. That statement should be tested against the likely device definition, risk class, comparator technology, clinical workflow and user population[2]. Early regulatory interaction can be useful when classification or evidence expectations are uncertain. Regulatory engagement does not guarantee authorization, but it can reduce avoidable divergence between development activities and submission expectations[17].

Evidence, quality and cybersecurity are commercialization assets

Regulatory authorization is not simply an administrative milestone. It depends on a body of evidence showing that the product performs as intended and that risks are controlled over the product lifecycle. For SaMD, IMDRF describes clinical evaluation through valid clinical association, analytical/technical validation and clinical validation. Medical-device development also requires traceability between user needs, design inputs, verification, validation and risk controls[12,18].

For startups, building these activities into development can be more efficient than reconstructing them retrospectively. Quality-system documentation, version control, complaint handling, supplier controls and cybersecurity practices also affect investor and partner confidence because they demonstrate whether the organization can reproduce and maintain the product after launch[17]. FDA's current digital-health guidance

emphasizes lifecycle management, cybersecurity and controlled software changes; its final guidance on predetermined change control plans provides a pathway for certain planned AI-enabled device modifications to be reviewed prospectively[19].

AI-enabled health products add further concerns because performance may vary across populations and data environments, and updates can alter safety or effectiveness[20]. WHO recommends attention to transparency, human oversight, data quality, accountability and lifecycle governance[21]. In the European Union, developers may also need to consider the interaction between the MDR/IVDR and the AI Act for qualifying high-risk systems[22].

Table II. Regulatory planning questions across the product lifecycle

Stage	Core question	Evidence/documentation focus	Commercial consequence
Concept	What is the intended medical purpose and user?	Intended-use statement, preliminary classification, risk concept	Determines pathway, claims and development burden
Prototype	Can design inputs and risks be traced?	Design history, verification plan, usability and cybersecurity requirements	Reduces redesign and supports diligence
Validation	Does the product perform in the intended population and setting?	Analytical/technical and clinical performance; risk-benefit evidence	Supports authorization and customer confidence
Submission/launch	Are manufacturing/deployment controls reproducible?	Quality system, labelling, technical file, software configuration	Enables lawful market entry and scalable deployment
Post-market	Can safety, performance and changes be monitored?	Vigilance, complaints, cybersecurity, update/change controls	Supports maintenance, expansion and responsible iteration

Data governance and contracting

Data are central to many digital-health and AI business models, but possession of data does not automatically confer unrestricted rights to reuse, combine or commercialize them[11]. Startups should document the provenance of training and validation datasets, permissions for secondary use, de-identification or anonymization approach where relevant, cross-border restrictions, and obligations to hospitals, investigators, vendors and patients[21]. Contracts should also address model improvement, derived data, security responsibilities, audit rights, breach response and termination[23,24].

In India, the Digital Personal Data Protection Act, 2023 and the Digital Personal Data Protection Rules, 2025 create a contemporary framework for processing digital personal data. Health-tech developers therefore need to consider privacy obligations alongside sector-specific medical-device requirements. Privacy compliance and medical-device compliance overlap but are not substitutes for one another: a product may satisfy one framework while still failing the other[23,24].

From regulatory clearance to market access

Authorization permits market entry but does not guarantee adoption[2]. Clinical users and health systems may also require workflow compatibility, training, service support, procurement eligibility, health-economic justification, reimbursement or evidence of operational benefit[3]. Open-access studies of technology translation and

implementation emphasize that commercial planning[4] should begin before the regulatory submission is complete and should include customers, clinicians, payers and procurement stakeholders[10].

The same principle applies to IP. A patent portfolio can strengthen negotiating position, but value depends on whether the claims cover a product that can be manufactured, regulated, reimbursed and purchased. Conversely, a product with regulatory authorization but uncertain ownership or restrictive third-party licences can be difficult to finance or acquire. Commercial readiness therefore depends on the quality of the links between technical, clinical, IP, regulatory and business evidence rather than on any single certificate or filing[2,8].

Figure 1. Integrated IP-regulatory-commercialization framework



Figure 1. A staged framework for coordinating intended use, intellectual property, regulatory classification, evidence generation, market access and post-market iteration. The sequence is iterative; feedback from validation, regulatory review and market use may require earlier decisions to be revisited.

A staged strategy for health-tech startups

The synthesis supports a staged rather than sequential strategy[2]. At the discovery stage, founders should document the clinical problem, ownership, prior disclosures and third-party dependencies. During feasibility, intended use and likely regulatory classification should be tested while the protectable technical features are refined[10]. During design and validation, the IP portfolio, quality system, evidence plan, cybersecurity controls and data agreements should mature together. Before launch, freedom to operate, labelling, manufacturing or deployment controls, reimbursement and distribution arrangements should be reviewed as a single commercialization package[16]. After launch, post-market data and software or hardware changes should be governed in a manner consistent with the authorized product and the continuing IP strategy[17].

Table III. Practical integrated checklist for startup decision-making

Decision point	IP action	Regulatory/clinical action	Business action
Before public disclosure	Record inventorship; assess confidentiality and filing options	Define intended use and preliminary risk	Confirm founder/institutional ownership
Before design freeze	Update prior-art/FTO review; protect key know-how	Confirm classification; map verification/validation	Test customer need and pricing assumptions
Before clinical validation	Align claims with product version and licences	Agree endpoints, population, comparator and data plan	Plan funding, sites and reimbursement evidence
Before submission/launch	Check assignments, licences, trademarks and territorial coverage	Complete technical file, quality and cybersecurity documentation	Finalize distribution, procurement and support model
After launch	Track new inventions and confidentiality	Monitor safety/performance; control changes	Use real-world feedback without drifting beyond authorized claims

Indian context and implications for startup planning

India combines a large health need, expanding digital infrastructure and an active med-tech startup ecosystem with a regulatory framework that is still evolving for software-intensive products[3]. Recent CDSCO guidance on medical device software provides additional clarity on scope, classification, technical documentation and quality requirements under the Medical Devices Rules, 2017. Indian innovators considering global markets may nevertheless face parallel requirements in the United States, European Union or other jurisdictions, making early market prioritization important[15,16,25].

For resource-constrained startups, global regulatory expansion is unlikely to be efficient if every market is pursued simultaneously. A rational sequence may prioritize the jurisdiction that best matches clinical access, evidence availability, financing and commercial partnerships, while preserving IP filing options in markets that remain strategically important. This is a business decision rather than a universal rule and should be revisited as evidence and partnerships develop.

Limitations

This is a narrative review and not a systematic review; it does not quantify the frequency or magnitude of startup failure attributable to individual IP or regulatory factors. Regulatory requirements also change over time and vary by product class, jurisdiction and intended use. The framework should therefore be interpreted as a strategic planning aid rather than legal, patent, reimbursement or regulatory advice for a specific product. Product-specific decisions require review of the current law and direct guidance from appropriately qualified professionals and regulators.

Conclusion

Health-tech commercialization is more coherent when IP, regulatory, clinical and business decisions are planned together from an early stage. Patents, trade secrets, copyright, trademarks and contracts protect different assets, while regulatory strategy determines the claims, evidence, quality controls and lifecycle obligations required for lawful market entry. Neither a strong patent position nor regulatory authorization alone establishes commercial viability. For startups, the practical objective is to reduce avoidable uncertainty by clarifying ownership, intended use, evidence requirements, data rights, freedom to operate, quality processes and post-market

responsibilities before major capital is committed. This integrated approach cannot eliminate development risk, but it provides a more defensible basis for iteration, licensing, investment and responsible scale-up.

Declarations

- Funding: None.
- Competing interests: None declared.
- Ethics approval: Not applicable.
- Data availability: No primary research dataset was generated or analysed for this narrative review. All sources cited are publicly accessible.
- Acknowledgment: None.

References

[1] World Health Organization, World Intellectual Property Organization, World Trade Organization. Promoting access to medical technologies and innovation: intersections between public health, intellectual property and trade. 2nd ed. Geneva: World Health Organization; 2020.

[2] Lottes AE, Cavanaugh KJ, Chan YYF, Devlin VJ, Goergen CJ, Jean R, et al. Navigating the regulatory pathway for medical devices-a conversation with the FDA, clinicians, researchers, and industry experts. J Cardiovasc Transl Res. 2022;15:927-43.

[3] Gupta P, Rai C, Shahi A, Sharma M, Choudhury R, Kotwal A. A comprehensive roadmap for MedTech innovations uptake into the public healthcare system in India. Front Digit Health. 2023;5:1268010.

[4] Roosink M, van Gemert-Pijnen L, Verdaasdonk R, Kelders SM. Assessing health technology implementation during academic research and early-stage development: support tools for awareness and guidance: a review. Front Digit Health. 2024;6:1386998.

[5] World Intellectual Property Organization. Frequently asked questions: patents [Internet]. Geneva: WIPO; 2026. Available from: https://www.wipo.int/en/web/patents/faq_patents, accessed on August 29, 2026.

[6] World Intellectual Property Organization. WIPO guide to trade secrets and innovation [Internet]. Geneva: WIPO; 2024. Available from: https://www.wipo.int/publications/en/details.jsp?id=4748, accessed on August 29, 2026.

[7] World Intellectual Property Organization. Trademarks [Internet]. Geneva: WIPO; 2026. Available from: https://www.wipo.int/en/web/trademarks/, accessed on August 29, 2026.

[8] Van Norman GA, Eisenkot R. Technology transfer: from the research bench to commercialization. Part 1: intellectual property rights-basics of patents and copyrights. JACC Basic Transl Sci. 2017;2:85-97.

[9] Hopkins BP. Swimming upstream: developing and commercializing diabetes products in a patent protected world. J Diabetes Sci Technol. 2013;7:768-75.

[10] Kearney SJ, Lowe A, Lennerz JK, Parwani A, Bui MM, Wack K, et al. Bridging the gap: the critical role of regulatory affairs and clinical affairs in the total product life cycle of pathology imaging devices and software. Front Med (Lausanne). 2021;8:765385.

[11] Largent EA, Karlawish J, Wexler A. From an idea to the marketplace: identifying and addressing ethical and regulatory considerations across the digital health product-development lifecycle. BMC Digit Health. 2024;2:41.

[12] International Medical Device Regulators Forum. Software as a Medical Device (SaMD): clinical evaluation. IMDRF/SaMD WG/N41FINAL:2017 [Internet]. 2017. Available from: https://www.imdrf.org/documents/software-medical-device-samd-clinical-evaluation, accessed on August 29, 2026.

[13] US Food and Drug Administration. Digital Health Policy Navigator [Internet]. Silver Spring: FDA. Available from: https://www.fda.gov/medical-devices/digital-health-center-excellence/digital-health-policy-navigator, accessed on August 29, 2026.

[14] European Parliament and Council of the European Union. Regulation (EU) 2017/745 of 5 April 2017 on medical devices [Internet]. Official Journal of the European Union; 2017. Available from: https://eur-lex.europa.eu/eli/reg/2017/745/oj, accessed on August 29, 2026.

[15] Central Drugs Standard Control Organisation. Medical Devices Rules, 2017 [Internet]. New Delhi: Directorate General of Health Services, Ministry of Health & Family Welfare, Government of India. Available from: https://cdsco.gov.in/opencms/opencms/en/Acts-and-rules/Medical-Devices-Rules/, accessed on August 29, 2026.

[16] Central Drugs Standard Control Organisation. Guidance document on Medical Device Software under MDR-2017 [Internet]. New Delhi: CDSCO; 2026. Available from: https://www.cdsco.gov.in/opencms/opencms/en/Medical-Device-Diagnostics/Medical-Device-Diagnostics/, accessed on August 29, 2026.

[17] US Food and Drug Administration. Marketing submission recommendations for a predetermined change control plan for artificial intelligence-enabled device software functions: guidance for industry and Food and Drug Administration staff [Internet]. Silver Spring: FDA; 2025. Available from: https://www.fda.gov/regulatory-information/search-fda-guidance-documents/marketing-submission-recommendations-predetermined-change-control-plan-artificial-intelligence, accessed on August 29, 2026.

[18] European Commission. Guidance-MDCG endorsed documents and other guidance [Internet]. Brussels: European Commission; 2026. Available from: https://health.ec.europa.eu/medical-devices-sector/new-regulations/guidance-mdcg-endorsed-documents-and-other-guidance_en, accessed on August 29, 2026.

[19] US Food and Drug Administration. Guidances with digital health content [Internet]. Silver Spring: FDA; 2026. Available from: https://www.fda.gov/medical-devices/digital-health-center-excellence/guidances-digital-health-content, accessed on August 29, 2026.

[20] European Parliament and Council of the European Union. Regulation (EU) 2024/1689 laying down harmonised rules on artificial intelligence [Internet]. Official Journal of the European Union; 2024. Available from: https://eur-lex.europa.eu/legal-content/EN/TXT/?uri=celex:32024R1689, accessed on August 29, 2026.

[21] World Health Organization. Ethics and governance of artificial intelligence for health: WHO guidance. Geneva: World Health Organization; 2021.

[22] World Health Organization. Regulatory considerations on artificial intelligence for health. Geneva: World Health Organization; 2023.

[23] Ministry of Law and Justice, Government of India. Digital Personal Data Protection Act, 2023 (Act No. 22 of 2023) [Internet]. New Delhi: Government of India; 2023. Available from: https://www.indiacode.nic.in/bitstream/123456789/22037/2/a2023-22.pdf, accessed on August 29, 2026.

[24] Ministry of Electronics and Information Technology, Government of India. Digital Personal Data Protection Rules, 2025 [Internet]. New Delhi: MeitY; 2025. Available from: https://www.meity.gov.in/documents/act-and-policies/digital-personal-data-protection-rules-2025-gDOxUjMtQWa, accessed on August 29, 2026.

[25] Bhatt A. Bio-entrepreneurs' bugbear: regulatory rigmarole. Perspect Clin Res. 2024;15:122-7.